Developer docs
API playgroundTry for free, no card

Search company profiles

CytoReason

Full company profile

uuid0000ncy

Namestring
CytoReason
Legal namestring
CytoReason Ltd
Websiteurl
cytoreason.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

CytoReason develops AI-powered computational disease models that integrate molecular, clinical, and patient-level data to map treatments, patient groups, and disease mechanisms for pharmaceutical R&D. Founded in 2016 in Tel Aviv, Israel, the company's core platform trains an evidence graph on hundreds of thousands of data points spanning transcriptomic, proteomic, single-cell, and clinical datasets, enabling comparison of drugs across multiple diseases or multiple drugs within a single disease. The product portfolio includes the central Disease Model Platform plus specialized modules for Target Profiling, Disease Subtypes, Indication Assignment, Patient Stratification, Competitive Analysis, and Standard of Care MoA, as well as disease-specific models such as IBD and Influenza. In January 2026, CytoReason launched LINA, an AI agent for pharmaceutical R&D built on the computational disease models and NVIDIA NIM microservices, designed to automate scientific workflows while grounding responses in mechanistic biology to avoid the hallucinations common in general-purpose language models.

CytoReason serves a concentrated base of top-tier pharmaceutical companies through multi-year enterprise licensing agreements that include upfront payments, milestone payments, and option fees. Disclosed customers include Pfizer (partnership since 2019 across more than 20 diseases with a deal potentially worth up to $110M over five years), Sanofi (multiple IBD-related expansions, with the latest valued at up to $16M), Takeda, Ferring Pharmaceuticals, and Poolbeg Pharma. The company reports that 5-6 of the world's top 10 pharma companies use its technology, and revenue streams span technology licensing, research collaboration services, and licensing options. Distribution is primarily direct enterprise sales with a dedicated business development team targeting pharmaceutical R&D leaders, supplemented by channel partnerships (notably Helixrus for the Korean market).

The company has raised a total of $100M in disclosed funding, including $20M from Pfizer in September 2022 and an $80M round in July 2024 led by OurCrowd with NVIDIA, Pfizer, and Thermo Fisher Scientific as strategic investors. The company holds ISO 27001 certification, has established a US hub in Cambridge, Massachusetts, and has published extensively in peer-reviewed journals including Nature, Cell, and Nature Biotechnology. Operating geographies span Israel (headquarters), the United States (Cambridge hub), and Asia Pacific (via Helixrus channel partner).

Short descriptiontext

CytoReason develops AI-powered computational disease models for pharmaceutical R&D, serving top global pharma companies including Pfizer, Sanofi, and Takeda with platform modules for target identification, patient stratification, and drug portfolio analysis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational disease modeling, AI drug discovery, pharmaceutical R&D platform, computational biology software, biomarker discovery analytics
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Software Publishers5132
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Prepackaged Software7372
Product category
AI Drug Discovery Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing and Platform Access
TypeSubscription Recurring
Description

Multi-year licensing agreements with pharmaceutical companies for access to computational disease models and AI platform. Deals include upfront payments, milestone payments, and option fees.

cytoreason.com
2Research Collaboration Services
TypeProfessional Services
Description

Funded research collaborations where CytoReason provides AI analysis and disease model development services to pharma partners. Includes supplementary project support funding.

cytoreason.com
3Technology Licensing Options
TypeLicensing Royalties
Description

Partners can license CytoReason's platform and disease models with options to extend, generating additional licensing revenue.

cytoreason.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise pharmaceutical licensing - custom pricing based on scope and partnership terms
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Multi-year agreements with pharmaceutical companies including upfront investment, milestone payments, and licensing options. Pfizer $20M equity investment plus up to $110M total deal value over 5 years.

cytoreason.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

CytoReason develops an AI-powered computational disease model platform that integrates molecular, clinical, and patient-level data to map treatments, patient groups, and disease mechanisms for pharmaceutical R&D. The company licenses disease-specific models (e.g., IBD, influenza) and, as of January 2026, offers LINA, an AI agent built on NVIDIA NIM microservices that allows researchers to query the disease models conversationally while avoiding hallucinations common in general-purpose language models.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Five of the world's top ten pharma companies use CytoReason's technology to identify new opportunities, shorten trial phases, reduce development costs, and increase likelihood of drug approval
+2 more records
Product overview1 text field

CytoReason offers a unified AI-powered computational disease model platform that serves as the core product, supplemented by specialized modules and disease-specific models. The flagship Disease Model Platform integrates petabytes of molecular data into decision-ready models, while LINA (an AI agent introduced in January 2026) acts as an intelligent interface built on NVIDIA NIM microservices. The platform includes therapeutic-area-specific modules for Target Profiling, Disease Subtypes, Indication Assignment, Patient Stratification, Competitive Analysis, and Standard of Care MoA analysis. The portfolio also includes disease-specific models such as IBD and Influenza disease models. The architecture enables scientists to identify targets, stratify patients, compare drugs across diseases, and make portfolio-level decisions.

Product and service4 records
1CytoReason Disease Model Platform
CategoryCore platform
2LINA
CategoryAI agent
3IBD Disease Model
CategoryDisease-specific model
4Influenza Disease Model
CategoryDisease-specific model
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierSecondaryTypeTechnology or IntegrationAnnounced on2026-01-12
Description

Validating LINA AI agent capabilities. Jointly published data at UEG Congress demonstrating technology's potential for target discovery insights in ulcerative colitis and Crohn's disease.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

Third expansion of collaboration with multi-year agreement valued at up to $16 million. Fifth commercial deal of 2025. Partnership enables Sanofi scientists to utilize CytoReason's computational models for IBD and other therapeutic areas.

Strategic tierSecondaryTypeTechnology or IntegrationAnnounced on2024-05-21
Description

AI-driven novel target identification collaboration for IBD using CytoReason's cell-centered AI technology combined with Ferring's therapeutic knowledge.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2024-05-15
Description

Data collaboration integrating Foundation's IBD Plexus real-world data platform with CytoReason's computational disease models to advance IBD research and enable more targeted therapies.

Strategic tierSecondaryTypeTechnology or IntegrationAnnounced on2022-11-29
Description

AI analysis partnership for influenza disease progression data. Completed computational AI influenza disease model using Poolbeg's human challenge trial data to identify drug targets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-20
Description

Expanded multi-year partnership with $20M equity investment and options to license CytoReason's platform and disease models, potentially worth up to $110M over five years. Collaboration active since 2019 focusing on immune-mediated and immuno-oncology diseases across over 20 diseases.

7Helixrus
Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-04-12
Description

Commercial partnership for Korean pharmaceutical market. Helixrus represents CytoReason's AI platform and professional services in South Korea, leveraging deep knowledge of Korean pharmaceutical market and extensive network.

cytoreason.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning, targeting large pharma partnerships. Most direct competitor to CytoReason in scaling AI-bio platforms for enterprise pharma; has raised and deployed substantially more capital.

TypeDirect peer
Description

Machine-learning-driven drug discovery and development company building predictive models of disease from large-scale data. Directly comparable to CytoReason in using AI/ML on biological data to serve pharma R&D partnerships.

TypeDirect peer
Description

AI-driven precision medicine company focused on small-molecule drug discovery using its AI platform. Now operating under Recursion post-merger; historically a direct competitor using computational platforms to design and prioritize drug candidates for pharma partners.

TypeDirect peer
Description

Computational chemistry and drug design platform providing physics-based software plus AI-driven molecular design for pharma R&D. Direct competitor in serving pharma with computational drug discovery tooling, with a strong software/enterprise orientation.

TypeDirect peer
Description

AI-driven drug discovery company using knowledge graphs and machine learning to identify new drug targets. Comparable to CytoReason in applying AI to biomedical knowledge to prioritize targets and serve pharma partners.

6Isomorphic Labs
TypeEmerging player
Description

Alphabet-owned commercial spinout of DeepMind's AlphaFold work, building an AI-driven drug discovery engine for pharma. Direct peer in AI-for-pharma with deep-pocketed backing; competing for the same enterprise pharma relationships.

TypeDirect peer
Description

AI biotech using federated learning on multimodal patient data to accelerate drug discovery and development. Direct peer serving pharma with AI platforms, with comparable federated/multi-modal data emphasis and similar funding stage.

TypeDirect peer
Description

AI-powered drug discovery platform integrating human data and computation to accelerate development. Direct peer in end-to-end AI-driven drug discovery with a focus on cardiovascular, oncology, and neurodegenerative diseases.

9Iambic Therapeutics
TypeEmerging player
Description

AI-driven drug discovery company developing its own pipeline using physics-informed neural networks for molecular design. Comparable AI-bio platform; smaller and earlier-stage but with similar enterprise pharma ambitions.

TypeBroad incumbent
Description

Strategic investor and infrastructure provider for CytoReason via BioNeMo and NIM microservices. While not a direct competitor, NVIDIA's expanding life-sciences AI platform (BioNeMo, Clara) is a broad incumbent whose roadmap could compete with or enable CytoReason's product surface.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CytoReason

AI Drug Discovery Platformcytoreason.com

CytoReason develops AI-powered computational disease models for pharmaceutical R&D, serving top global pharma companies including Pfizer, Sanofi, and Takeda with platform modules for target identification, patient stratification, and drug portfolio analysis.

What CytoReason does

CytoReason develops AI-powered computational disease models that integrate molecular, clinical, and patient-level data to map treatments, patient groups, and disease mechanisms for pharmaceutical R&D. Founded in 2016 in Tel Aviv, Israel, the company's core platform trains an evidence graph on hundreds of thousands of data points spanning transcriptomic, proteomic, single-cell, and clinical datasets, enabling comparison of drugs across multiple diseases or multiple drugs within a single disease. The product portfolio includes the central Disease Model Platform plus specialized modules for Target Profiling, Disease Subtypes, Indication Assignment, Patient Stratification, Competitive Analysis, and Standard of Care MoA, as well as disease-specific models such as IBD and Influenza. In January 2026, CytoReason launched LINA, an AI agent for pharmaceutical R&D built on the computational disease models and NVIDIA NIM microservices, designed to automate scientific workflows while grounding responses in mechanistic biology to avoid the hallucinations common in general-purpose language models.

CytoReason serves a concentrated base of top-tier pharmaceutical companies through multi-year enterprise licensing agreements that include upfront payments, milestone payments, and option fees. Disclosed customers include Pfizer (partnership since 2019 across more than 20 diseases with a deal potentially worth up to $110M over five years), Sanofi (multiple IBD-related expansions, with the latest valued at up to $16M), Takeda, Ferring Pharmaceuticals, and Poolbeg Pharma. The company reports that 5-6 of the world's top 10 pharma companies use its technology, and revenue streams span technology licensing, research collaboration services, and licensing options. Distribution is primarily direct enterprise sales with a dedicated business development team targeting pharmaceutical R&D leaders, supplemented by channel partnerships (notably Helixrus for the Korean market).

The company has raised a total of $100M in disclosed funding, including $20M from Pfizer in September 2022 and an $80M round in July 2024 led by OurCrowd with NVIDIA, Pfizer, and Thermo Fisher Scientific as strategic investors. The company holds ISO 27001 certification, has established a US hub in Cambridge, Massachusetts, and has published extensively in peer-reviewed journals including Nature, Cell, and Nature Biotechnology. Operating geographies span Israel (headquarters), the United States (Cambridge hub), and Asia Pacific (via Helixrus channel partner).

CytoReason firmographics

Firmographics
Name
CytoReason
Legal name
CytoReason Ltd
Website
https://cytoreason.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
CytoReason develops AI-powered computational disease models for pharmaceutical R&D, serving top global pharma companies including Pfizer, Sanofi, and Takeda with platform modules for target identification, patient stratification, and drug portfolio analysis.
Ownership category
akta.pro rank

CytoReason industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Software Publishers (5132), Scientific Research and Development Services (5417)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Computational disease modeling
  • AI drug discovery
  • Pharmaceutical R&D platform
  • Computational biology software
  • Biomarker discovery analytics

Where CytoReason is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

CytoReason business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Technology Licensing and Platform Access: Multi-year licensing agreements with pharmaceutical companies for access to computational disease models and AI platform. Deals include upfront payments, milestone payments, and option fees.
  2. Research Collaboration Services: Funded research collaborations where CytoReason provides AI analysis and disease model development services to pharma partners. Includes supplementary project support funding.
  3. Technology Licensing Options: Partners can license CytoReason's platform and disease models with options to extend, generating additional licensing revenue.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise pharmaceutical licensing - custom pricing based on scope and partnership terms

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

CytoReason product offering

Product offering

Core offering

CytoReason develops an AI-powered computational disease model platform that integrates molecular, clinical, and patient-level data to map treatments, patient groups, and disease mechanisms for pharmaceutical R&D. The company licenses disease-specific models (e.g., IBD, influenza) and, as of January 2026, offers LINA, an AI agent built on NVIDIA NIM microservices that allows researchers to query the disease models conversationally while avoiding hallucinations common in general-purpose language models.

Product overview

CytoReason offers a unified AI-powered computational disease model platform that serves as the core product, supplemented by specialized modules and disease-specific models. The flagship Disease Model Platform integrates petabytes of molecular data into decision-ready models, while LINA (an AI agent introduced in January 2026) acts as an intelligent interface built on NVIDIA NIM microservices. The platform includes therapeutic-area-specific modules for Target Profiling, Disease Subtypes, Indication Assignment, Patient Stratification, Competitive Analysis, and Standard of Care MoA analysis. The portfolio also includes disease-specific models such as IBD and Influenza disease models. The architecture enables scientists to identify targets, stratify patients, compare drugs across diseases, and make portfolio-level decisions.

Differentiator

Problem solved

Functional benefit

Products and services

  • CytoReason Disease Model Platform
  • LINA
  • IBD Disease Model
  • Influenza Disease Model

Quantifiable outcome

  • Five of the world's top ten pharma companies use CytoReason's technology to identify new opportunities, shorten trial phases, reduce development costs, and increase likelihood of drug approval
  • +2 more outcomes

Companies that use CytoReason

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

CytoReason technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

CytoReason partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered secondary and core.

  • TakedasecondaryTechnology or Integration · 12 January 2026Validating LINA AI agent capabilities. Jointly published data at UEG Congress demonstrating technology's potential for target discovery insights in ulcerative colitis and Crohn's disease.
  • SanoficoreStrategic or Co-development Partner · 9 January 2026Third expansion of collaboration with multi-year agreement valued at up to $16 million. Fifth commercial deal of 2025. Partnership enables Sanofi scientists to utilize CytoReason's computational models for IBD and other therapeutic areas.
  • Ferring PharmaceuticalssecondaryTechnology or Integration · 21 May 2024AI-driven novel target identification collaboration for IBD using CytoReason's cell-centered AI technology combined with Ferring's therapeutic knowledge.
  • Crohn's & Colitis FoundationsecondaryStrategic or Co-development Partner · 15 May 2024Data collaboration integrating Foundation's IBD Plexus real-world data platform with CytoReason's computational disease models to advance IBD research and enable more targeted therapies.
  • Poolbeg PharmasecondaryTechnology or Integration · 29 November 2022AI analysis partnership for influenza disease progression data. Completed computational AI influenza disease model using Poolbeg's human challenge trial data to identify drug targets.
  • PfizercoreStrategic or Co-development Partner · 20 September 2022Expanded multi-year partnership with $20M equity investment and options to license CytoReason's platform and disease models, potentially worth up to $110M over five years. Collaboration active since 2019 focusing on immune-mediated and immuno-oncology diseases across over 20 diseases.
  • HelixrussecondaryChannel Partner/ Reseller/ Distributor · 12 April 2022Commercial partnership for Korean pharmaceutical market. Helixrus represents CytoReason's AI platform and professional services in South Korea, leveraging deep knowledge of Korean pharmaceutical market and extensive network.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

CytoReason competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning, targeting large pharma partnerships. Most direct competitor to CytoReason in scaling AI-bio platforms for enterprise pharma; has raised and deployed substantially more capital.
  • Insitro: Machine-learning-driven drug discovery and development company building predictive models of disease from large-scale data. Directly comparable to CytoReason in using AI/ML on biological data to serve pharma R&D partnerships.
  • Exscientia: AI-driven precision medicine company focused on small-molecule drug discovery using its AI platform. Now operating under Recursion post-merger; historically a direct competitor using computational platforms to design and prioritize drug candidates for pharma partners.
  • Schrödinger: Computational chemistry and drug design platform providing physics-based software plus AI-driven molecular design for pharma R&D. Direct competitor in serving pharma with computational drug discovery tooling, with a strong software/enterprise orientation.
  • BenevolentAI: AI-driven drug discovery company using knowledge graphs and machine learning to identify new drug targets. Comparable to CytoReason in applying AI to biomedical knowledge to prioritize targets and serve pharma partners.
  • Owkin: AI biotech using federated learning on multimodal patient data to accelerate drug discovery and development. Direct peer serving pharma with AI platforms, with comparable federated/multi-modal data emphasis and similar funding stage.
  • Valo Health: AI-powered drug discovery platform integrating human data and computation to accelerate development. Direct peer in end-to-end AI-driven drug discovery with a focus on cardiovascular, oncology, and neurodegenerative diseases.

Emerging players

  • Isomorphic Labs: Alphabet-owned commercial spinout of DeepMind's AlphaFold work, building an AI-driven drug discovery engine for pharma. Direct peer in AI-for-pharma with deep-pocketed backing; competing for the same enterprise pharma relationships.
  • Iambic Therapeutics: AI-driven drug discovery company developing its own pipeline using physics-informed neural networks for molecular design. Comparable AI-bio platform; smaller and earlier-stage but with similar enterprise pharma ambitions.

Broad incumbents

  • NVIDIA (BioNeMo / Clara): Strategic investor and infrastructure provider for CytoReason via BioNeMo and NIM microservices. While not a direct competitor, NVIDIA's expanding life-sciences AI platform (BioNeMo, Clara) is a broad incumbent whose roadmap could compete with or enable CytoReason's product surface.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

CytoReason social profiles

Digital presence

CytoReason compliance and trust

Trust signal

Compliance1 record

CytoReason financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CytoReason leadership team

Management profile

Number of profiles

Profiles20 records

CytoReason funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CytoReason M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CytoReason

What does CytoReason do?

CytoReason develops an AI-powered computational disease model platform that integrates molecular, clinical, and patient-level data to map treatments, patient groups, and disease mechanisms for pharmaceutical R&D. The company licenses disease-specific models (e.g., IBD, influenza) and, as of January 2026, offers LINA, an AI agent built on NVIDIA NIM microservices that allows researchers to query the disease models conversationally while avoiding hallucinations common in general-purpose language models.

Is CytoReason a public or private company?

CytoReason is a private company. It is classified as venture growth investor backed and is currently operating.

When was CytoReason founded?

CytoReason was founded in 2016. It employs 101 to 250 people.

Where is CytoReason based?

CytoReason is headquartered in Tel Aviv, Israel, in the Middle East region.

How does CytoReason make money?

Three revenue lines are on record. Technology Licensing and Platform Access are the primary driver. The others are research Collaboration Services and technology Licensing Options.

Who are CytoReason's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Exscientia, Schrödinger, BenevolentAI, Owkin and Valo Health. Emerging players are Isomorphic Labs and Iambic Therapeutics. NVIDIA (BioNeMo / Clara) is listed as a broad incumbent.

Does CytoReason have an API?

No public API is recorded for CytoReason.

What industry is CytoReason in?

CytoReason's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireIsrael Innovation Authority Invests Approx. NIS 70 Million in National Infrastructure for AI Models Based on Bio DataThe Israel Innovation Authority announced a NIS 70 million investment in the Israel BioToken Factory Initiative (IBFI), a consortium of NVIDIA, Teva, Sheba Medical Center, and universities. The initiative will develop a shared infrastructure for AI models based on biological data, aiming to improve drug discovery and personalized medicine.PR NewswireCytoReason unveils LINA, an AI Agent accelerated by NVIDIA for Pharma R&D, built on computational disease modelsAt the 2026 JP Morgan Healthcare Conference, CytoReason unveiled LINA, an AI agent for pharmaceutical R&D built on its computational disease models and NVIDIA NIM microservices, designed to help researchers analyze molecular, clinical, and patient-level data while avoiding hallucinations common in general-purpose language models. The agent runs on NVIDIA accelerated computing infrastructure and enables pharma research teams to conduct complex biological analyses efficiently at scale. CytoReason is validating LINA with pharmaceutical partners including Takeda, which jointly published data at the UEG Congress demonstrating the technology's potential for generating target discovery insights.CytoreasonCytoReason extends its collaboration with Sanofi to advance AI-driven drug discoveryCytoReason announced the expansion of its collaboration with Sanofi for the third time, securing a multi-year agreement valued at up to $16 million. The deal marks CytoReason's fifth commercial deal of 2025 and builds on its track record working with half of the world's top twenty pharmaceutical companies. The AI-powered computational disease modeling platform will enable Sanofi's R&D teams to extract insights from molecular and clinical data to support drug discovery decisions.PR NewswireCytoReason extends its collaboration with Sanofi to advance AI-driven drug discoveryCytoReason announced the expansion of its collaboration with Sanofi for the third time, signing a multi-year agreement valued at up to $16 million. This marks CytoReason's fifth commercial deal of 2025 and further solidifies its partnership with the immunology-focused pharmaceutical company. The AI-powered computational disease modeling technology enables Sanofi's R&D teams to extract insights from molecular and clinical data to support drug development decisions.YahooCytoReason extends its collaboration with Sanofi to advance AI-driven drug discoveryCytoReason extended its collaboration with Sanofi for a third time, signing a multi-year agreement valued at up to $16 million. The deal builds on its track record with half of the world's top twenty pharma companies. The partnership aims to use CytoReason's AI-driven disease modeling to inform R&D decisions.BioPharmaTrendFrom Animals to Algorithms: How AI Brings Drug Testing Closer to Human BiologyResearchers from academia, pharma, and biotech are increasingly adopting new approach methodologies (NAMs), particularly AI-based approaches, to replace or reduce animal testing in preclinical drug development, driven by the high failure rate of drugs in clinical trials and regulatory pressure from agencies like the FDA. Companies such as Quris-AI, Axiom, Certara, CytoReason, and Vivodyne are actively developing AI models for toxicity prediction, ADME modeling, and digital disease models using human cell, organoid, and organ-on-chip data. The FDA Modernization Act 2.0 and recent regulatory shifts signal a move toward making animal studies the exception rather than the norm for preclinical safety testing over the next 3–5 years.FortunebusinessinsightsArtificial Intelligence (AI) In Drug Discovery Market Report, 2030The global AI in drug discovery market is projected to grow from USD 3.00 billion in 2022 to USD 7.94 billion by 2030, registering a CAGR of 12.2%, driven by the pharmaceutical industry's need to reduce drug development costs and timelines. North America dominated the market with a 69.33% share in 2022, supported by strategic alliances between biopharma players and AI technology providers. Key industry collaborations include Insilico Medicine's USD 1.2 billion deal with Sanofi and Pfizer's USD 110 million partnership with CytoReason, reflecting the sector's rapid consolidation and investment.The Jerusalem PostWhat are the challenges integrating AI into biotechnology? - opinionAI is increasingly integrated into biotechnology, with a reported $80 million funding round for Israeli AI-biotech company CytoReason, which involved Nvidia and Pfizer. The global AI in biotechnology market is projected to grow significantly, from $5.4 billion in 2024 to $26.3 billion over the next decade. This trend indicates continued advancements in AI-driven techniques revolutionizing biotech applications.PYMNTS.comTrending: Billion-Dollar Investments Drive AI Surge in HealthcareSpring Health raised $100 million in Series E funding, pushing its valuation to $3.3 billion, while CytoReason raised $80 million for AI drug discovery. AWS and GE HealthCare announced a partnership to use AI foundation models to unlock healthcare data. These investments aim to scale AI applications in mental health and pharmaceutical research.